Novo Nordisk A/S (NVO) research: valuation against peers, fundamentals over time, risk and news coverage
NVO
Novo Nordisk A/SNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHNovo Nordisk Shares Sink as CEO Admits Pipeline Doubts
Novo Nordisk's stock fell sharply after its CEO conceded the pipeline is the company's central weakness and investors pushed back on the sales targets management offered.
- BREAKING STORYBEARISHAnalyst Desks Fan Out Across Biotech and Consumer as China Auto Demand Cracks
Sell-side research activity clustered in clinical-stage biotech and consumer discretionary names, with upgrades for ConocoPhillips, SharkNinja, BridgeBio and Cogent offset by reductions at Middleby and Neurogene. The sharper signal came from China, where July passenger vehicle retail sales fell 20% year over year.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.